This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Setrusumab
DrugBank Accession Number
DB14778
Background

Setrusumab is under investigation in clinical trial NCT01406548 (Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density).

Type
Biotech
Groups
Investigational
Synonyms
  • Setrusumab
External IDs
  • BPS804

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Setrusumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Setrusumab.
AducanumabThe risk or severity of adverse effects can be increased when Aducanumab is combined with Setrusumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Setrusumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Setrusumab.
AmivantamabThe risk or severity of adverse effects can be increased when Setrusumab is combined with Amivantamab.
AnifrolumabThe risk or severity of adverse effects can be increased when Anifrolumab is combined with Setrusumab.
AnsuvimabThe risk or severity of adverse effects can be increased when Setrusumab is combined with Ansuvimab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Setrusumab.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Setrusumab.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
FPW3780T3E
CAS number
1847394-95-9

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentHypophosphatasia (HPP)1
2CompletedTreatmentOsteogenesis Imperfecta (OI)1
2CompletedTreatmentOsteogenesis Imperfecta Type III / Osteogenesis Imperfecta Type IV / Osteogenesis Imperfecta, Type I1
2CompletedTreatmentOsteopenia (Disorder) / Osteoporosis1
2WithdrawnTreatmentChronic-kidney Disease Stage 5D on Stable Hemodialysis1
2WithdrawnTreatmentOsteogenesis Imperfecta (OI)1
2, 3Not Yet RecruitingTreatmentOsteogenesis Imperfecta (OI)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at May 20, 2019 14:26 / Updated at February 21, 2021 18:54